Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant Efficacy in Insomnia with Comorbid Nocturia
NCT05597020Phase 4Completed
- Sponsor
- Idorsia
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial in insomnia disorder and nocturia comparing 50 mg daridorexant with Placebo (2 arms). Primary endpoint: Subjective Total Sleep Time at 4 weeks. Started Feb 2023; status: completed.
02
Drugs
daridorexant
03
Conditions
insomnia disordernocturia
Beyond the preview
Go deeper on NCT05597020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597020.